ABSTRACT
Nanotechnology is used to overcome fundamental flaws in today's marketed pharmaceuticals that obstruct therapy, like restricted solubility and quick release of drugs into the bloodstream. In both human and animal researches, melatonin was demonstrated to regulate glucose levels. Despite the fact that melatonin is quickly transported through the mucosa, its sensitivity to be oxidized creates a difficulty in achieving the required dose. Additionally, due to its variable absorption and poor oral bioavailability necessitates the development of alternative delivery methods. The study aimed to synthesize melatonin loaded chitosan/lecithin (Mel-C/L) nanoparticles to be assessed in the treatment of streptozotocin (STZ)-induced diabetes in rats. The antioxidant, anti-inflammatory, and cytotoxicity properties of nanoparticles were estimated to determine the safety of manufactured nanoparticles for in vivo studies. In addition, Mel-C/L nanoparticles were administered to rats for eight weeks after inducing hyperglycemia. The therapeutic effect of Mel-C/L nanoparticles was assessed in all experimental groups by detecting insulin and blood glucose levels; observing improvements in liver and kidney functions as well as histological and immunohistochemical evaluation of rats' pancreatic sections. The results proved that Mel-C/L nanoparticles showed remarkable anti-inflammatory, anti-coagulant, and anti-oxidant effects, in addition to its efficiency in reducing blood glucose levels of STZ-induced diabetic rats and great ability to promote the regeneration of pancreatic beta (ß)-cells. Furthermore, Mel-C/L nanoparticles elevated the insulin level; and decreased the elevated levels of urea, creatinine and cholesterol. In conclusion, nanoparticles application decreased the administrated melatonin dose that in turn can diminish the side effects of free melatonin administration.
Subject(s)
Chitosan , Diabetes Mellitus, Experimental , Hyperglycemia , Insulin-Secreting Cells , Melatonin , Humans , Animals , Rats , Lecithins , Melatonin/pharmacology , Streptozocin , Diabetes Mellitus, Experimental/drug therapy , Blood Glucose , Hyperglycemia/drug therapy , Antioxidants/pharmacology , InsulinABSTRACT
Background: Several reports of unheeded complications secondary to the current mass international rollout of SARS-COV-2 vaccines, one of which is myocarditis occurring with the FDA fully approved vaccine, Pfizer, and others. Main body of the abstract: Certain miRNAs (non-coding RNA sequences) are involved in the pathogenesis in viral myocarditis, and those miRNAs are interestingly upregulated in severe COVID-19. We hypothesize that the use of mRNA-based vaccines may be triggering the release of host miRNAs or that trigger the occurrence of myocarditis. This is based on the finding of altered host miRNA expression promoting virus-induced myocarditis. Short conclusion: In conclusion, miRNAs are likely implicated in myocarditis associated with mRNA vaccines. Our hypothesis suggests the use of miRNA as a biomarker for the diagnosis of mRNA vaccine-induced myocarditis. Additionally, the interplay between viral miRNA and the host immune system could alter inflammatory profiles, hence suggesting the use of therapeutic inhibition to prevent such complications.
ABSTRACT
Growth and meat production are the most relevant targets for animal breeders, there are strong relationships between animal growth regulation, body composition and meat quality. Therefore, it is essential to identify the genetic factors that are controlling growth, carcass, and meat quality traits and to explore the correlations between identified genes of those traits. Identification of candidate genes may shift rabbit breeding from classical to modern approaches, which offer great potential to accelerate genetic improvement plans, especially in developing countries. The current work reviews several genes and mutations affecting growth, carcass and meat quality traits. These candidate genes and mutations can be incorporated into MAS programs to improve rabbit breeds especially local breeds, provided that a reasonable proportion of trait additive genetic variance is explained by the significant marker. Furthermore, we highlighted the indispensable need for more researches investigating candidate genes for different traits.
Subject(s)
Body Composition , Meat , Rabbits , Animals , Phenotype , Meat/analysis , Body Weight/genetics , Body Composition/genetics , MutationABSTRACT
Purpose Microaggressions and how they affect underrepresented college students have been frequently documented. However, there is a lack of literature on the experiences of underrepresented communication sciences and disorders (CSD) students. The purpose of this study is to understand how underrepresented post baccalaureate, undergraduate, and graduate students in CSD experience microaggressions in their academic programs. Method A 19-item electronic survey was developed by American Speech-Language-Hearing Association's Multicultural Issues Board and distributed via multiple online platforms. A diverse group of 155 underrepresented CSD students completed the survey. A multistage qualitative thematic analysis was used to analyze students' experiences. Results Students (64.51%) who completed the survey have experienced microaggressions in their academic programs. Prominent themes of students' descriptions of microaggressions included feelings of otherness, damaging generalization, maltreatment from faculty, and maltreatment from peers. Students reported various responses to microaggressions including identity management strategies, disengaging, and working hard to exceed expectations and to prove themselves. Conclusions This study illustrates the ways that underrepresented CSD students experience symbolic violence from clients, peers, and faculty. It has implications for the need to cultivate more inclusive learning and social environments in CSD programs. Further research is needed to explore the ramifications of microaggressions and ways to effectively reduce and eventually eradicate them. Supplemental Material https://doi.org/10.23641/asha.15240723.
Subject(s)
Communication , Students , Faculty , Humans , Peer Group , Surveys and Questionnaires , United StatesABSTRACT
Following the decline in Physical Activity (PA) due to COVID-19 restrictions in the form of government mandated lockdowns and closures of public spaces, the modulatory effect of physical exercise on immunity is being heavily revisited. In an attempt to comprehend the wide discrepancy in patient response to COVID-19 and the factors that potentially modulate it, we summarize the findings relating PA to inflammation and immunity. A distinction is drawn between moderate intensity and high intensity physical exercise based on the high lactate production observed in the latter. We hypothesize that, the lactate production associated with high intensity anaerobic exercise is implicated in the modulation of several components of the innate and adaptive immunity. In this review, we also summarize these immunomodulatory effects of lactate. These include increasing serum IL-6 levels, the main mediator of cytokine storms, as well as affecting NK cells, Macrophages, Dendritic cells and cytotoxic T-lymphocytes. The implications of high lactate levels in athletic performance are highlighted where athletes should undergo endurance training to increase VO2 max and minimize lactate production. Tumor models of hypoxia were also reported where lactate levels are elevated leading to increased invasiveness and angiogenesis. Accordingly, the novel lactate blocking strategy employed in cancer treatment is evaluated for its potential benefit in COVID-19 in addition to the readily available beta-blockers as an antagonist to lactate. Finally, we suggest the diagnostic/prognostic purpose of the elevated lactate levels that can be determined through sweat lactate testing. It is the detrimental effect of lactate on immunity and its presence in sweat that qualify it to be used as a potential non-invasive marker of poor COVID-19 outcome.
Subject(s)
COVID-19 Drug Treatment , Lactic Acid/antagonists & inhibitors , Anaerobiosis/immunology , COVID-19/immunology , COVID-19/physiopathology , Exercise/physiology , Humans , Inflammation/immunology , Interleukin-6/blood , Lactic Acid/immunology , Lactic Acid/metabolism , Models, Immunological , Pandemics , SARS-CoV-2ABSTRACT
ABO blood groups is a cheap and affordable test that can be immediately retrieved from COVID-19 patients at the diagnosis. There is increasing evidence that non-O blood groups have both higher susceptibility and higher severity of COVID-19 infections. The reason behind such relationship seems elusive. Regarding susceptibility, Non-O individuals have Anti-A antibodies which can prevent viral entry across ACE-2 receptors, moreover, Non-O individuals are at higher risk of autoimmunity, hypercoagulable state, and dysbiosis resulting in an augmented tendency for vascular inflammatory sequelae of COVID-19. We can conclude, on the diagnostic level, that ABO blood groups can be potentially used for risk stratification of affected COVID-19 patients, to anticipate the deterioration of patients at higher risk for complications. On a therapeutic level, plasma from normal O blood group individuals might potentially replace the use of convalescent serum for the treatment of COVID-19.